C orbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) stock has reached a 52-week low, trading at $9.1, reflecting a period of significant pressure for the biopharmaceutical company. With a market ...

PALO ALTO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Orbus Therapeutics, Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of eflornithine to treat ...

Corbus Pharmaceuticals (CRBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...